TAK
Price:
$14.81
Market Cap:
$6.65T
Takeda Pharmaceutical Company Limited engages in the research, development, manufacture, marketing, and out-licensing of pharmaceutical products in Japan, the United States, Europe, Canada, Latin America, Russia, rest of Asia, and internationally. It offers pharmaceutical products in the areas of gastroenterology, rare diseases, plasma derived therapies, oncology, and neuroscience. The company provides its products under the Entyvio, Gattex/Revestive, Takecab, Alofisel, Dexilant, Natpara, Adynovate/Adynovi, Takhzyro, Livtencity, Elaprase, Replagal, Advate, Vpriv, Gammagard Liquid/Kiovig, Hyqvia, Cuvitru, Exkivity, Velcade, Leuplin/Enantone, Adcetris, Vyvansese, Trintellix, and Alunbrig brand...[Read more]
Industry
Drug Manufacturers - Specialty & Generic
IPO Date
2010-01-05
Stock Exchange
NYSE
Ticker
TAK
According to Takeda Pharmaceutical Company Limited’s latest financial reports and current stock price. The company's current ROE is 2.08%. This represents a change of 301.45% compared to the average of 0.52% of the last 4 quarters.
The mean historical ROE of Takeda Pharmaceutical Company Limited over the last ten years is 3.41%. The current 2.08% ROE has changed -39.03% with respect to the historical average. Over the past ten years (40 quarters), TAK's ROE was at its highest in in the June 2017 quarter at 7.19%. The ROE was at its lowest in in the March 2015 quarter at -10.55%.
Average
3.41%
Median
4.08%
Minimum
-6.82%
Maximum
9.36%
Discovering the peaks and valleys of Takeda Pharmaceutical Company Limited ROE, unveiling quarterly and yearly fluctuations to gain insights into the company’s financial performance and market dynamics, offering valuable data for investors and analysts alike.
Maximum Annual Increase = 676.04%
Maximum Annual ROE = 9.36%
Minimum Annual Increase = -258.02%
Minimum Annual ROE = -6.82%
Year | ROE | Change |
---|---|---|
2024 | 1.98% | -60.30% |
2023 | 4.99% | 23.24% |
2022 | 4.05% | -44.31% |
2021 | 7.27% | 676.04% |
2020 | 0.94% | -55.72% |
2019 | 2.12% | -77.39% |
2018 | 9.36% | 54.20% |
2017 | 6.07% | 47.50% |
2016 | 4.11% | -160.31% |
2015 | -6.82% | -258.02% |
The current ROE of Takeda Pharmaceutical Company Limited (TAK) is less than than its 3-year, less than than its 5-year, and less than than its 10-year historical averages
3-year avg
3.67%
5-year avg
3.84%
10-year avg
3.41%
Takeda Pharmaceutical Company Limited’s ROE is greater than Viatris Inc. (-3.20%), greater than Elanco Animal Health Incorporated (-20.61%), less than Zoetis Inc. (46.65%), greater than Emergent BioSolutions Inc. (-98.39%), less than Prestige Consumer Healthcare Inc. (12.68%), less than Amphastar Pharmaceuticals, Inc. (25.42%), greater than Deciphera Pharmaceuticals, Inc. (-52.42%), less than Pacira BioSciences, Inc. (7.32%), less than Collegium Pharmaceutical, Inc. (49.14%), less than SIGA Technologies, Inc. (51.39%), less than Indivior PLC (812.66%), less than Esperion Therapeutics, Inc. (26.20%), greater than Catalent, Inc. (-26.99%), greater than Evotec SE (-15.59%), less than Eagle Pharmaceuticals, Inc. (4.41%), less than Neurocrine Biosciences, Inc. (14.86%), less than Phibro Animal Health Corporation (0.91%), greater than Teva Pharmaceutical Industries Limited (-6.77%), less than Haleon plc (6.54%), less than Bausch Health Companies Inc. (3.27%),
Company | ROE | Market cap |
---|---|---|
-3.20% | $13.45B | |
-20.61% | $7.46B | |
46.65% | $85.73B | |
-98.39% | $397.86M | |
12.68% | $3.68B | |
25.42% | $2.21B | |
-52.42% | $2.21B | |
7.32% | $638.86M | |
49.14% | $1.20B | |
51.39% | $550.26M | |
812.66% | $3.01B | |
26.20% | $323.77M | |
-26.99% | $10.86B | |
-15.59% | $1.19B | |
4.41% | $55.19M | |
14.86% | $12.13B | |
0.91% | $788.20M | |
-6.77% | $20.48B | |
6.54% | $47.12B | |
3.27% | $2.28B |
One of the best ways to find valuable stocks to invest in is to build a custom made screener in your Excel or Google Sheets spreadsheet. This allows you to compare thousands of companies like Takeda Pharmaceutical Company Limited using the financials and key metrics that matter to you in a single view.
The easiest way to set this up is to use the Wisesheets add-on and set your spreadsheet like this:
Covering all these metrics from financial, data, dividend data, key metrics and more you can get all the data you want for over 50+ exchanges worldwide.
Get your free trial here.
The easiest way to analyze a company like Takeda Pharmaceutical Company Limited or any others is to create a spreadsheet model that automatically retrieves all of the stock data you need.
Using Wisesheets you can set up a spreadsheet model like this with simple spreadsheet formulas. If you change the ticker you can get all of the data automatically updated for you.
Whether you need live data, historical price data, financials, dividend data, key metrics, analyst estimates, or anything else...Wisesheets has you covered.
What is the ROE?
How can you use the ROE?
What is Takeda Pharmaceutical Company Limited's ROE?
How is the ROE calculated for Takeda Pharmaceutical Company Limited (TAK)?
What is the highest ROE for Takeda Pharmaceutical Company Limited (TAK)?
What is the 3-year average ROE for Takeda Pharmaceutical Company Limited (TAK)?
What is the 5-year average ROE for Takeda Pharmaceutical Company Limited (TAK)?
How does the current ROE for Takeda Pharmaceutical Company Limited (TAK) compare to its historical average?